Why Did the FDA Recall BIOCELL Implants?

The FDA initiated the July 2019 Allergan BIOCELL recall after its analysis of adverse event reports in the MAUDE database confirmed a dramatic over-representation of Allergan products in BIA-ALCL cases. The FDA had first warned of a possible BIA-ALCL link in January 2011, but as case counts grew through the 2010s, the Allergan-specific signal became undeniable: by mid-2019, Allergan BIOCELL implants accounted for approximately 85% of reported BIA-ALCL cases despite holding a significantly smaller share of the breast implant market. The FDA determined that BIOCELL recipients faced approximately 6 times the BIA-ALCL risk of patients with other manufacturers' products. The FDA requested a worldwide recall, and Allergan complied on July 24, 2019. The recall was the largest breast implant recall in FDA history.

France Recalled BIOCELL Implants One Year Earlier

A critical fact in the failure-to-warn litigation is that French health regulator ANSM suspended marketing authorization for Allergan BIOCELL textured implants in December 2018 — a full year before the U.S. recall. France's ANSM had independently identified the disproportionate risk from Allergan's macro-textured surface versus other manufacturers. This timeline means that Allergan had direct regulatory knowledge of the specific BIOCELL risk — not just general textured implant risk — well before the U.S. action. MDL 2921 plaintiffs cite the French recall as evidence that Allergan failed to act on actionable safety information in a timely manner, reinforcing the failure-to-warn narrative from 2018 through the July 2019 U.S. recall.

What the FDA Recommends for Patients With BIOCELL Implants

The FDA recommends that asymptomatic patients with recalled Allergan BIOCELL implants do NOT undergo prophylactic removal solely because of the recall, as the absolute risk of developing BIA-ALCL, while elevated relative to other implants, remains low in absolute terms. The FDA recommends that patients with BIOCELL implants receive routine follow-up with their plastic surgeon and promptly report any new symptoms — particularly late-onset seroma (sudden fluid accumulation), swelling, or lumps — for immediate evaluation. Any symptomatic patient should seek ultrasound-guided aspiration of the fluid and cytological testing for lymphoma cells. For purposes of legal claims, the FDA's recommendation against prophylactic removal does not prevent patients from choosing explantation after consulting with their surgeon, and recall-motivated explant surgery may still support legal claims for surgery costs.